April 16th 2024
A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Sabizabulin Deemed Safe in Metastatic Castration-Resistant Prostate Cancer
July 14th 2022In the interview, Mark Markowski, MD, discussed how the findings from the phase 1/2 trial of sabizabulin in patients with metastatic castration-resistant prostate cancer this may influence future research with the oral agent.
Read More
Enzalutamide Use in Patients With mHSPC Who Received Prior Local Therapy
July 8th 2022Neal Shore, MD, FACS, discusses the purpose behind investigating enzalutamide in a cohort of patients with metastatic hormone-sensitive prostate cancer who were previously treated with local therapy as a post-hoc analysis of the ARCHES study.
Watch
VISION Trial Shows Survival Benefit of Lutetium Radioligand for mCRPC
July 5th 2022During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.
Read More
SPOTLIGHT Shines on Inadequacy of Standard Imaging in Prostate Cancer
June 24th 2022Mark T. Fleming, MD, discusses the potential impact of positive data from the phase 3 SPOTLIGHT study, which assessed the how 18F-rhPSMA-7.3 PET scan use in male patients with biochemical recurrence of prostate cancer affects upstaging in comparison with conventional imaging.
Watch
CARD Trial Shows Survival and QOL Benefits of Cabazitaxel in mCRPC
June 15th 2022During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of cabazitaxel for patients with metastatic castration-resistant prostate cancer. This is part 1 of 2 articles based on this event.
Read More
Radiotherapy Can Be Paired with Next-Gen Hormonal Therapy in Phase 3 HRLPC Trials
June 9th 2022According to the phase 3 ATLAS trial, radiotherapy can be administered with next-generation hormonal therapy in phase 3 trials of patients with high-risk localized or locally advanced prostate cancer.
Read More